Clincosm LogoSign in Get a demo

Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Experimental Sepsis

Sponsor
Air Force Military Medical University, China (Other)
Overall Status
Unknown status
CT.gov ID
NCT02185118
Collaborator
(none)
50
Enrollment
1
Location
1
Arm
49
Duration (Months)
1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Sepsis is a major cause of death in intensive care units. Despite the investigators improved understanding, which has reduced the risk of dying with sepsis, the number of people who die each year continues to increase due to an overall increase in the number of cases.In our previous study, the investigators have showed that 100% oxygen or 0.5 minimum alveolar concentration (MAC) isoflurane/sevoflurane in 60% oxygen protect mouse macrophage cell line against in-vitro sepsis induced by lipopolysaccharide (LPS).

In this study, the investigator hypothesized that treatment of 100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen protected against clinical in-vitro models of sepsis induced by LPS or plasma from septic patients.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

100% oxygen or 0.5 MAC isoflurane/sevoflurane in 60% oxygen would inhibit increases of tumor necrosis factor (TNF)-alpha, interleukin-1beta, interleukin-6 in the cell culture supernatant after stimulation of LPS or plasma from septic patients, and also inhibit the nuclear location of nuclear factor-kappa B p65 subunit.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
In-vitro Experimental Study About Effects of Subanesthetic Isoflurane/Sevoflurane in 60% Oxygen on Clinical In-vitro Sepsis
Study Start Date :
Jun 1, 2014
Anticipated Primary Completion Date :
Jun 1, 2018
Anticipated Study Completion Date :
Jul 1, 2018

Arms and Interventions

Arm Intervention/Treatment
Experimental: oxygen plus isoflurane/sevoflurane

All human peripheral blood mononuclear cells (PBMCs) were from patients with non sepsis/non SIRS/non infection. The above cells were treated with oxygen or oxygen plus isoflurane/sevoflurane after stimulation of lipopolysaccharide/plasma from septic patients.

Drug: oxygen
Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
Other Names:
  • 100% oxygen

    • Drug: Sevoflurane
    Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients. Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
    Other Names:
  • subanesthetic sevoflurane in 60% oxygen

    • Drug: Isoflurane
    Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients. Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients.
    Other Names:
  • subanesthetic isoflurane in 60% oxygen

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Subcellular location of Nuclear Factor-KAPPA B p65 subunit [within 10 hours after the intervention]

    Secondary Outcome Measures

    1. tumor necrosis factor-alpha [within 10 hours after the intervention]

    2. interleukin- 1 beta [within 10 hours after the intervention]

    3. interleukin 6 [within 10 hours after the intervention]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:

    • Human PBMCs were only isolated from the adult patients without sepsis/SIRS/infectious diseases.

    • The plasma for induction of clinical in-vitro sepsis, was only isolated from adult patients with sepsis.

    Exclusion Criteria:
    • Patients who had been selected for other clinical trials in the 3 months before.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Department of Anesthesiology, Xijing Hospital, Fourth Military Medical University, Xi'an Shaanxi China 710032

    Sponsors and Collaborators

    • Air Force Military Medical University, China

    Investigators

    • Principal Investigator: Lichao Hou, M.D., Ph.D., Air Force Military Medical University, China

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Lichao Hou, M.D., Ph.D, Air Force Military Medical University, China
    ClinicalTrials.gov Identifier:
    NCT02185118
    Other Study ID Numbers:
    • NSFC-81171839
    • Chinese NSFC
    First Posted:
    Jul 9, 2014
    Last Update Posted:
    Jul 9, 2014
    Last Verified:
    Jul 1, 2014
    Additional relevant MeSH terms:
    Sepsis
    Toxemia
    Sevoflurane
    Isoflurane

    Study Results

    No Results Posted as of Jul 9, 2014